HealthDay News — Pfizer Inc. announced that its experimental COVID-19 pill slashed the risk of hospitalization and death by 89% in infected high-risk people.

The 5-day treatment, when given within 3 days of infection, was so effective in a clinical trial that an independent monitoring committee recommended the trial be stopped early, Pfizer said.

The antiviral pill, the second of its kind to show the power to guard against severe COVID-19, appears to be even more effective than a similar offering from Merck. Merck’s pill, molnupiravir, halved the risk of severe disease in high-risk patients. British regulators cleared the pill for use this week in people who are diagnosed with COVID-19 and have at least one risk factor for severe illness, The Washington Post reported. In the United States, a US Food and Drug Administration advisory committee plans to meet shortly after Thanksgiving to assess Merck’s pill. Merck has said it can produce 10 million treatment courses in 2021.


Continue Reading

As for Pfizer’s antiviral pill, the findings have not been peer-reviewed or published yet, but the data will be submitted to regulators “as soon as possible,” the company said in a news release. The drug, which will be sold under the name Paxlovid, is designed to prevent the coronavirus from making copies of itself.

Pfizer has already started making the drug and expects to produce more than 180,000 pill packs by the end of this year, boosting that to a total of 50 million in 2022, The Post reported. No price for the pill has been disclosed by the company.

The Washington Post Article